An interventional study of Health-related messages in Diabetes and Renal Failure , Chronic, sponsored by Nantes University Hospital. Recruiting at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Nantes University Hospital · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 352 studies in Diabetes Mellitus with a site in France — 47 open to participants now, 53 under way, 3 of them phase 3. Diabetes Mellitus · France.
Among the 352 studies in Diabetes Mellitus with a site in France, this one has the largest planned enrollment of the 242 interventional ones that give a count, is one of 11 that started in 2026, is one of 100 with no phase, reaches primary completion later than 45 of the 51 other live ones, and was the 349th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →47 of the 352 studies in Diabetes Mellitus with a site in France are open now. Recruiting first, the newest first:
Pfizer · Sites in France, United States, Brazil and 8 more countries
Ages 18+
Centre Hospitalier Sud Francilien · Sites in France
Ages 18+
University Hospital, Grenoble · Sites in France
Ages 18+
Insulet Corporation · Sites in France
Ages 2+
Solsius · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
352 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 32 · Phase 3 83 · Phase 4 27
First in 1990; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 125,000 is above the median of 80 across 6,027 interventional studies indexed under Diabetes Mellitus.
Median enrollment 187 across the 242 interventional studies, 268 across the 110 observational. Of the 263 that completed or were terminated, 71 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
144 of 352 have an industry lead sponsor. The 10 most frequent:
Nantes University Hospital is the lead sponsor of 839 studies on the registry; 189 are open to participants now.
Nantes University Hospital has 4 studies filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
13 of the studies in Diabetes Mellitus with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07455994Centre Hospitalier Universitaire de Saint EtienneDysautonomia in Children With Type 1 Diabetes | 2026-12 |
| NCT05795582Centre Hospitalier Universitaire de NiceUpstroke Time Measured by Photoplethysmography | 2026-12-14 |
| NCT06782997CHU de ReimsPerformance of the Electroretinogram, Performed and Interpreted by an Advanced Practice Nurse, in the Screening for Diabetic Retinopathy. | 2026-12-17 |
| NCT06066801Assistance Publique - Hôpitaux de ParisBedside Bone Biopsy in Diabetic Foot Osteomyelitis | 2027-03 |
| NCT07910721SolsiusContinuous Monitoring of Plantar Temperature Variations Using Connected Insoles and a Mobile Application for Diabetic Foot. | 2027-04-10 |
Add all 13 to your calendar (.ics) → With an account.
Among the 352 studies in Diabetes Mellitus with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical study is to establish if the use of public health-related messages, designed and disseminated to a targeted population, will result in tangible improvements in patient outcomes and healthcare practices.
Specific health-related messages oriented towards patients, through their biological results and HealthCare Professionals (HCPs), will be sent to participants included in the intervention group. The control group will not receive any health-related message (routine care).
The aim is to evaluate if this intervention leads to differences in Major Adverse Renal and Cardiovascular Events (MARCE), compared to routine care (no dissemination of health messages) in patients suffering in diabetes and renal failure.
Main inclusion criteria:
Main exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive an health-related message included in the biological results form. A short graphical illustration will indicate the patient-risk level according the biological results and video detailing national recommendations. HCPs will receive a SIGNAL BIO message which was elaborated on evidence-based treatments and/or strategy for patients with diabetes.
Other: Health-related messages
Participants will get as in the routine care, no message will be disseminated for this group.
Patient will be included in the intervention according to the laboratory's randomization arm.The intervention consists in delivering patient information messages in laboratory reports, providing access to an educational video for patients and a specific message for the prescribing physician in the intervention arm, without modifying patient care.
Major Adverse Renal and Cardiovascular Events (MARCE) occurrence
Change in Major Adverse Renal and Cardiovascular Events (MARCE) occurrence defined as a composite outcome including the following items (first occurring): * All-cause death * Myocardial infarction (universal definition) * Stroke (universal definition) * Sustained (over 45 days) use of renal replacement therapy * Heart failure leading to hospitalization (definition by the European Society of Cardiology)
Time frame: 2 years after randomization and dissemination of health-related messages
Specific health outcomes
Change in specific health outcomes (separately analysed): * All-cause death * Myocardial infarction * Stroke * Sustained (over 1 month) use of renal replacement therapy * Heart failure leading to hospitalization * Lower limb amputation, with special information on the site of amputation (toe, transmetatarsal, transtibial, transfemoral) * Arterial revascularization in the coronary, cerebrovascular and/or lower aorta/lower limb territories * Severe diabetic retinopathy (laser procedure, eye surgery for diabetes complication and intravitreal injection associated with specific drug delivery and/or their combinations
Time frame: 2 years after the randomization and dissemination of health-related messages
Reimbursement claims of medications of special interest and visits to general practitioners and to specialists in cardiology, nephrology and diabetology
Change in Reimbursement claims of medications of special interest and visits to general practitioners and to specialists in cardiology, nephrology and diabetology
Time frame: 6 months and 2 years after randomization and dissemination of health-related messages
Biological characteristics
Changes in biological results of: lipids, liver and renal functions, blood cell count, HbA1c, CRP , Blood chemistry and Blood and urine urea
Time frame: 2 years before and after randomization and dissemination of health-related messages
Impact on medical costs
Changes between groups: * in euros of patients healthcare costs, * in type of costs (consultation, hospitalisation, etc), * in euros of the intervention impact, * in QALY of cost-effectiveness
Time frame: 2 years after randomization and dissemination of health-related messages
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Jul 2029, 36 months after the start.
Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 36 months is above that.
Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: start Jun 2026 → Jul 2026 and primary completion Jun 2029 → Jul 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.